Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Voclosporin – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
Voclosporin is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data …
DUBLIN–(BUSINESS WIRE)–The “VAY736 (Ianalumab) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
VAY736 (IANALUMAB) acts as Antibody-dependent cell cytotoxicity, B-cell activation factor recep…
DUBLIN–(BUSINESS WIRE)–The “MIJ 821 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treat…
DUBLIN–(BUSINESS WIRE)–The “Global Mycosis Fungoides Therapeutics Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
The mycosis fungoides therapeutics market is poised to grow by $ 115.42 mn during 2021-2025, progressing …
DUBLIN–(BUSINESS WIRE)–The “Global Mycosis Fungoides Therapeutics Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
The mycosis fungoides therapeutics market is poised to grow by $ 115.42 mn during 2021-2025, progressing …
DUBLIN–(BUSINESS WIRE)–The “Global Mycosis Fungoides Therapeutics Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
The mycosis fungoides therapeutics market is poised to grow by $ 115.42 mn during 2021-2025, progressing …
DUBLIN–(BUSINESS WIRE)–The “Global Mycosis Fungoides Therapeutics Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
The mycosis fungoides therapeutics market is poised to grow by $ 115.42 mn during 2021-2025, progressing …
MIAMI–(BUSINESS WIRE)–#biotech–OrganaBio, LLC (“OrganaBio”) announces the launch of the HematoPAC™-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic cell therapies. These products provide a u…
MIAMI–(BUSINESS WIRE)–#biotech–OrganaBio, LLC (“OrganaBio”) announces the launch of the HematoPAC™-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic cell therapies. These products provide a u…
MIAMI–(BUSINESS WIRE)–#biotech–OrganaBio, LLC (“OrganaBio”) announces the launch of the HematoPAC™-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic cell therapies. These products provide a u…